

**SymPeptide<sup>®</sup> 226EL - XLash**  
**NOVEL PEPTIDE**  
**EYELASH / HAIR GROWTH**

**The information set forth herein does include proprietary and confidential information of Symrise and must be treated in confidence and not be used by the recipient hereof unless otherwise agreed to in writing by Symrise**

# CLINICAL STUDY ANTI HAIR LOSS

## Test design:


- Subjects: 24 subjects – male & female - with androgenetic alopecia (II–III stage of Hamilton’s scale for men and I-II stage of Ludwig’s scale for women, see *explanation in Appendix*)
- In androgenic alopecia, a progressive inversion of the normal anagen/telogen ratio due to the increase of the percentage of hair in rest phase is observed. A decrease in the number/ratio of hair in telogen phase to the anagen phase gives evidence of efficacy of the treatment
- Test area: scalp
- Test period: 3 months with measurements at 0, 45 and 90 days
- Hair shaved off in an area of 1cm<sup>2</sup>. 48 hours later, hair dyed with a black hair colour Test Products: double blind study - 12 subjects apply serum with 10% SymPeptide<sup>®</sup> 226EL and 12 apply serum without 226EL

# CLINICAL STUDY ANTI HAIR LOSS


## Protocol :

- Subjects spread 2ml of the product on the scalp and massage for 3-4 minutes without rinsing – once daily
- Wash their hair 48hours before each measurement and not to apply styling products during the 48 hours preceding the visit
- Digital image of 20-fold magnification (analyzed area 0.651cm<sup>2</sup>) taken by means of a epiluminescence microscopy system
- Area analysed by TrichoScan (Fotofinder Dermoscope and Trichoscan professional Ver. 2.0)
- Software analyzed the digital image and detected the number and percentage of hair in anagen phase and telogen phase in the area
- Measurements: hair growth evaluated as the following parameters by means of the phototrichogram analysis:
  - percentage and the number of anagen hair (growth phase)
  - percentage and the number of telogen hair (rest phase)

# CLINICAL STUDY PROTOCOL SCHEMATICALLY



# CLINICAL STUDY RESULTS - ANAGEN



✓ Serum with SymPeptide® 226EL showed more increase in anagen (growth phase) hair than serum without 226EL :

→ + 7.3% @ D45 and + 8.4% @ D90


→ Placebo : +4% @ D45 and + 6.8% @ D 90

✓ Statistical significance - p value (paired Ttest) versus placebo:

→ p=0.051 @D45

→ p=0.148 @D90

# CLINICAL STUDY RESULTS - TELOGEN



✓ Serum with SymPeptide® 226EL showed more decrease in telogen (rest phase) hair than serum without 226EL

→ -12.% @ D45 and -11.6% @ D90

→ Placebo : -6.3% @ D45 and -0.6% @ D90

✓ Statistical significance - p value (paired Ttest) versus placebo:

→ p=0.051 @D45

→ p=0.160 @D90

# CLINICAL STUDY DISCUSSION

- The percentage of anagen (growth phase) hair at the site treated with serum containing SymPeptide® 226EL showed more increase than the site treated with serum without 226EL
- The percentage of telogen (rest phase) hair at the site treated with SymPeptide® 226EL showed more decrease than the site treated with without 226EL
- Though the results are positive but not significant, they are interpreted by the test lab as good for a cosmetic ingredient, especially since the tested formulation is simple
- Better results could be expected by combining different actives and optimising the formulation



# SymPeptide<sup>®</sup> XLash – NEW GRADE




## SymPeptide<sup>®</sup> XLash:

- New preserved grade replacing SymPeptide<sup>®</sup> 226EL
- Preservatives: 0.1% Benzoic acid + 0.1% Sodium Benzoate solubilised in 0.45% Hexanediol and 0.45% Caprylyl Glycol
- Sold as 1000ppm (0.10% peptide) solution in Glycerin/Water
- Colorless to pale beige solution with very low odor – no impact on formulation
- Use level: 2-10%
- Soluble in water, ethanol and glycols
- Stability at pH 4-8 and temperature up to 100°C
- Bioavailable Lipo OligoPeptides (LOPs)
- Hair/eyelash growth enhancer

# APPENDIX ANDROGENETIC ALOPECIA

Also known as male pattern baldness, begins at the hairline

## MALE PATTERN



## FEMALE PATTERN



The Norwood–Hamilton scale of male-pattern baldness

Published in Expert Reviews in Molecular Medicine by Cambridge University Press 2002

# SYMRISE

## ALWAYS INSPIRING MORE...



### DISCLAIMER

These suggestions and data are based on information we believe to be reliable. They are offered in good faith, but without guarantee, as conditions and methods of use of our products are beyond our control. Symrise makes no warranties, either expressed or implied, as to the accuracy or appropriateness of this data. Symrise expressly disclaims any implied warranty of fitness for a particular use.

We recommend that prospective users determine for themselves the suitability of Symrise materials and suggestions for any use prior to their adoption. We also recommend that prospective users, as required, obtain approval from appropriate regulatory authorities. Suggestions for uses of our products or the inclusion of descriptive material from patents and the citation of specific patents in this publication should not be understood as recommending the use of our products in violation of any patent or as a permission or license to use any patent of Symrise.